About the Research Program
Mission
- Provides scientific and administrative oversight for preclinical chemoprevention agent development up to early phase I chemopreventive agent research utilizing physiological endpoints in healthy volunteers.
- Research includes all classes of agents (e.g. pharmaceuticals, micronutrients) and includes synthesis/extraction, and mechanistic studies (e.g. assays using high-throughput gene analysis technology, cell cultures from high-risk tissue, carcinogenesis related biochemical activities, technologies focusing on molecular targets and their modulation leading to the identification and optimization of promising chemopreventive agents).
- Assists extramural investigators to bridge the gap between discovery and clinical testing through management of the PREVENT Cancer Preclinical Drug Development Program.
- Works with DCP clinical research groups in clinical trials development, agent acquisition, IND - directed toxicology and related research.
- Communicates with extramural and intramural investigators and industry and provides technical support and research resources for chemopreventive agent development.
Staff
- Dan Boring, RPh, PhD
- Barbara Dunn, MD PhD
- Ronald Lubet, PhD
- Winfred Malone, PhD, MPH
- Marjorie Perloff, MD
- Danny Prince
- Philip C Prorok, PhD
- Robert Shoemaker
- Vernon Steele, PhD, MPH
- Chen Suen, PhD, RPh
Phone
(240) 276-7030
U.S. Mail Address
Chemopreventive Agent Development
Research Group, DCP, NCI
9609 Medical Center Drive
Rockville, MD 20850
Commercial Delivery Address
Chemopreventive Agent Development
Research Group, DCP, NCI
9609 Medical Center Drive
Rockville, MD 20850
Back to top
